Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||gastroesophageal junction adenocarcinoma||not applicable||ALX148 + Trastuzumab||Phase I||Actionable||In a Phase I trial, ALX148 and Herceptin (trastuzumab) combination treatment resulted in a partial response in 19% (4/21) and stable disease in 29% (6/21) of patients with gastric or gastroesophageal junction cancer that progressed on chemotherapy (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 2514-2514; NCT03013218).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.||Full reference...|